ESMO 2018 | CELESTIAL trial: assessing outcomes by AFP levels in HCC

R. Kate Kelley

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, speaks at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, on the results of the CELESTIAL study of cabozantinib, a multi-kinase inhibitor, in patients with advanced hepatocellular carcinoma, who have been previously treated with sorafenib (NCT01908426). She discusses the efficacy benefits that were previously reported, as well as the interesting sub analyses presented at ESMO 2018, including new data on how cabozantinib works according to subgroups of patients with varying levels of the alpha-fetoprotein (AFP) biomarker.

Share this video